Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil,...

Abstract

UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca.

Keywords

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakInterimMedicineBetacoronavirusInterim analysisVirologyCoronavirus InfectionsSars virusCoronavirusMEDLINEPandemicClinical trialInternal medicineGeographyBiologyOutbreakInfectious disease (medical specialty)

MeSH Terms

AdolescentAdultAgedBrazilCOVID-19COVID-19 VaccinesChAdOx1 nCoV-19Double-Blind MethodFemaleHumansMaleMiddle AgedSingle-Blind MethodSouth AfricaTreatment OutcomeUnited KingdomYoung Adult

Affiliated Institutions

Related Publications

Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

Bindu Bennet , Jayanthi Wolf , Rodrigo Laureano +1 more

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak that started in Wuhan, China, in 2019 resulted in a pandemic not seen for a century, and there is an ur...

2020 Toxicologic Pathology 47 citations

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh , Robert W. Frenck , Ann R. Falsey +22 more

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data re...

2020 New England Journal of Medicine 2665 citations

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Chih‐Cheng Lai , Tzu-Ping Shih , Wen‐Chien Ko +2 more

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously provisionally named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) in China at ...

2020 International Journal of Antimicrobia... 6277 citations

Characteristics of SARS-CoV-2 and COVID-19

Ben Hu , Hua Guo , Peng Zhou +1 more

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of acute re...

2020 Nature Reviews Microbiology 5269 citations

The proximal origin of SARS-CoV-2

Kristian G. Andersen , Andrew Rambaut , W. Ian Lipkin +2 more

SARS-CoV-2 is the seventh coronavirus known to infect humans; SARSCoV, MERS-CoV and SARS-CoV-2 can cause severe disease, whereas HKU1, NL63, OC43 and 229E are associated with mi...

2020 Nature Medicine 5448 citations

Publication Info

Year: 2020
Type: article
Volume: 397
Issue: 10269
Pages: 99-111
Citations: 4945
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

4945

OpenAlex

141

Influential

4073

CrossRef

Cite This

APA Style

                            
                                
                                    Merryn Voysey, 
                                
                                    Sue Ann Costa Clemens, 
                                
                                    Shabir A. Madhi
                                
                                et al.
                            
                            (2020). 
                            Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. 
                            The Lancet
                            , 397
                            (10269)
                            , 99-111.
                            https://doi.org/10.1016/s0140-6736(20)32661-1
                        

Identifiers

DOI: 10.1016/s0140-6736(20)32661-1
PMID: 33306989
PMCID: PMC7723445

Data Quality

Data completeness: 86%